Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?
Wang-Lopez Q, Chalabi N, Abrial C, Radosevic-Robin N, Durando X, Mouret-Reynier MA, Benmammar KE, Kullab S, Bahadoor M, Chollet P, Penault-Llorca F, Nabholtz JM. Wang-Lopez Q, et al. Crit Rev Oncol Hematol. 2015 Jul;95(1):88-104. doi: 10.1016/j.critrevonc.2015.02.011. Epub 2015 Mar 4. Crit Rev Oncol Hematol. 2015. PMID: 25900915 Review.
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
Nabholtz JM, Chalabi N, Radosevic-Robin N, Dauplat MM, Mouret-Reynier MA, Van Praagh I, Servent V, Jacquin JP, Benmammar KE, Kullab S, Bahadoor MR, Kwiatkowski F, Cayre A, Abrial C, Durando X, Bignon YJ, Chollet P, Penault-Llorca F. Nabholtz JM, et al. Int J Cancer. 2016 May 1;138(9):2274-80. doi: 10.1002/ijc.29952. Epub 2015 Dec 28. Int J Cancer. 2016. PMID: 26649807 Clinical Trial.
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet JM, Pèlegrin A, Larbouret C, Robert B. Leconet W, et al. Clin Cancer Res. 2017 Jun 1;23(11):2806-2816. doi: 10.1158/1078-0432.CCR-16-1316. Epub 2016 Dec 6. Clin Cancer Res. 2017. PMID: 27923843
[Evaluation of the immune infiltrate in breast cancer].
Radosevic-Robin N, Béguinot M, Penault-Llorca F. Radosevic-Robin N, et al. Bull Cancer. 2017 Jan;104(1):52-68. doi: 10.1016/j.bulcan.2016.11.010. Epub 2016 Dec 13. Bull Cancer. 2017. PMID: 27986267 Review. French.
Ki67 assessment in breast cancer: an update.
Penault-Llorca F, Radosevic-Robin N. Penault-Llorca F, et al. Pathology. 2017 Feb;49(2):166-171. doi: 10.1016/j.pathol.2016.11.006. Epub 2017 Jan 5. Pathology. 2017. PMID: 28065411
PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer.
Lusho S, Durando X, Bidet Y, Molnar I, Kossai M, Bernadach M, Lacrampe N, Veyssiere H, Cavaille M, Gay-Bellile M, Radosevic-Robin N, Abrial C. Lusho S, et al. Medicine (Baltimore). 2020 Dec 11;99(50):e23418. doi: 10.1097/MD.0000000000023418. Medicine (Baltimore). 2020. PMID: 33327268 Free PMC article.
68 results